BIO 2024
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending BIO 2024 in San Diego, USA, on the 3rd – 6th of June 2024.
The BIO International Convention is the largest biotechnology event of the year, with >20,000 industry leaders attending from across the globe. Physiomics’ CEO, Peter Sargent, and Head of Business Development, Hayley Close will be attending the event to meet with decision makers from leading pharma & biotech companies. Physiomics will be looking to identify opportunities where the company’s expertise in quantitative pharmacology and PKPD modelling can be applied to derisk R&D of therapeutics drugs, across indications for the companies attending.
If you are interested in meeting at BIO, please contact us through the partnering system or email Hayley directly at hclose@physiomics.co.uk.
We look forward to seeing you there!
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.